1.29
price down icon7.19%   -0.10
after-market アフターアワーズ: 1.30 0.01 +0.78%
loading
前日終値:
$1.39
開ける:
$1.34
24時間の取引高:
4.24M
Relative Volume:
1.03
時価総額:
$244.40M
収益:
$116.33M
当期純損益:
$-209.25M
株価収益率:
-0.6085
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
-19.88%
1か月 パフォーマンス:
-18.35%
6か月 パフォーマンス:
-34.18%
1年 パフォーマンス:
-58.65%
1日の値動き範囲:
Value
$1.28
$1.35
1週間の範囲:
Value
$1.28
$1.62
52週間の値動き範囲:
Value
$1.28
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
名前
Esperion Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
734-887-3903
Name
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
職員
240
Name
Twitter
@esperioninc
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
ESPR's Discussions on Twitter

ESPR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
1.29 244.40M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.61 71.47B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.19 47.98B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 47.20B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
14.85 17.02B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
307.36 13.80B 2.76B 1.11B 898.10M 22.77

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-18 開始されました Goldman Neutral
2024-12-17 開始されました Cantor Fitzgerald Overweight
2024-06-20 ダウングレード BofA Securities Neutral → Underperform
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-11-20 再開されました JP Morgan Neutral
2023-08-01 アップグレード Northland Capital Under Perform → Market Perform
2023-06-15 アップグレード BofA Securities Underperform → Buy
2023-03-16 ダウングレード BofA Securities Neutral → Underperform
2023-03-16 ダウングレード Northland Capital Market Perform → Under Perform
2023-03-07 アップグレード Credit Suisse Underperform → Neutral
2023-02-27 再開されました BofA Securities Neutral
2023-02-24 アップグレード Jefferies Hold → Buy
2023-02-03 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-08-03 ダウングレード Credit Suisse Neutral → Underperform
2022-05-05 アップグレード JP Morgan Underweight → Neutral
2022-03-10 開始されました H.C. Wainwright Buy
2021-10-19 ダウングレード Credit Suisse Outperform → Neutral
2021-10-14 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-05-05 ダウングレード Stifel Buy → Hold
2021-04-26 再開されました Credit Suisse Outperform
2021-03-11 開始されました Morgan Stanley Equal-Weight
2021-02-12 ダウングレード Jefferies Buy → Hold
2021-02-09 ダウングレード Goldman Neutral → Sell
2021-01-15 ダウングレード BofA Securities Buy → Neutral
2020-11-10 アップグレード Credit Suisse Neutral → Outperform
2020-09-29 再開されました JP Morgan Underweight
2020-08-11 ダウングレード Credit Suisse Outperform → Neutral
2020-04-01 再開されました BofA/Merrill Buy
2020-03-17 アップグレード Citigroup Neutral → Buy
2020-02-24 ダウングレード Northland Capital Outperform → Market Perform
2020-02-14 ダウングレード Citigroup Buy → Neutral
2019-09-16 アップグレード Goldman Sell → Neutral
2019-05-29 ダウングレード Goldman Neutral → Sell
2019-05-06 アップグレード BofA/Merrill Underperform → Neutral
2019-04-26 アップグレード Goldman Sell → Neutral
2019-03-13 アップグレード JP Morgan Underweight → Neutral
2019-01-07 繰り返されました Needham Strong Buy
2018-12-13 開始されました Goldman Sell
2018-10-29 アップグレード Northland Capital Market Perform → Outperform
2018-10-16 開始されました BTIG Research Buy
2018-08-17 アップグレード Citigroup Neutral → Buy
2018-07-11 ダウングレード Northland Capital Outperform → Market Perform
2018-05-03 ダウングレード JP Morgan Neutral → Underweight
2018-05-02 ダウングレード BofA/Merrill Buy → Underperform
すべてを表示

Esperion Therapeutics Inc (ESPR) 最新ニュース

pulisher
Apr 03, 2025

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Apr 03, 2025
pulisher
Apr 02, 2025

Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

Esperion Appoints Robert E. Hoffman as New Director - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com India

Mar 31, 2025
pulisher
Mar 24, 2025

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 13, 2025

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN

Mar 13, 2025
pulisher
Mar 11, 2025

Esperion stock hits 52-week low at $1.55 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Esperion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 08, 2025

Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Esperion Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Esperion Therapeutics Inc. (ESPR) reports earnings - Quartz

Mar 07, 2025
pulisher
Mar 07, 2025

Brokers Set Expectations for ESPR Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Esperion Therapeutics: Q4 Earnings Snapshot - Barchart

Mar 05, 2025
pulisher
Mar 05, 2025

Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics Q4 Loss Narrows - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Esperion Therapeutics stock surges over 9% on strong Q4 results By Investing.com - Investing.com Canada

Mar 04, 2025

Esperion Therapeutics Inc (ESPR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$9.72
price down icon 9.75%
$31.66
price down icon 3.03%
$97.21
price down icon 0.22%
$8.16
price down icon 5.77%
$102.88
price down icon 5.01%
$307.36
price down icon 1.57%
大文字化:     |  ボリューム (24 時間):